论文部分内容阅读
目的研究阿德福韦酯联合安络化纤丸对慢性乙型肝炎引起的失代偿期肝硬化抗病毒及抗纤维化治疗的效果。方法50例患者按1:1的比例随机分配到治疗组及对照组,两组均给予支持治疗,治疗组加用阿德福韦酯和安络化纤丸口服,疗程52周。结果治疗52周末Child-Pugh评分治疗组由10.4±2.3下降为6.2±2.4,对照组由10.3±2.2上升为10.6±1.9,t=7.042P<0.01;HBVDNA转阴率比较,治疗组58.33%,对照组8.33%,χ2=13.5,P<0.01;均存在差异且有统计学意义。结论阿德福韦酯联合安络化纤丸对慢性乙型肝炎引起的失代偿期肝硬化能显著地控制病毒复制,改善肝功能,降低Child-Pugh评分。
Objective To study the effect of adefovir dipivoxil combined with Anluo Huaxian Pills on antiviral and antifibrotic treatment of decompensated cirrhosis caused by chronic hepatitis B Methods Fifty patients were randomly assigned to the treatment group and the control group according to the ratio of 1: 1. Both groups were given supportive therapy. The treatment group was treated with adefovir dipivoxil and Anluohuaxian pill for 52 weeks. Results The Child-Pugh score at the 52nd week of treatment decreased from 10.4 ± 2.3 to 6.2 ± 2.4, while the control group increased from 10.3 ± 2.2 to 10.6 ± 1.9, t = 7.042 P <0.01. The negative conversion rate of HBVDNA was 58.33% The control group 8.33%, χ2 = 13.5, P <0.01; there are differences and statistically significant. Conclusions Adefovir dipivoxil combined with Anluo Huaxian Wan can significantly control the viral replication, improve liver function and reduce Child-Pugh score in decompensated cirrhosis caused by chronic hepatitis B patients.